Home The crystal structure of 1-methyl-2-nitroimidazole, C4H5N3O2
Article Open Access

The crystal structure of 1-methyl-2-nitroimidazole, C4H5N3O2

  • Yanan Qiao ORCID logo , Jun Yuan ORCID logo EMAIL logo , Changyuan Wan , Yuexia Li and Yong Wang ORCID logo
Published/Copyright: February 8, 2022

Abstract

C4H5N3O2, monoclinic, P21/c (no. 14), a = 4.0668(13) Å, b = 11.198(4) Å, c = 6.137(2) Å, β = 97.033(11)°, V = 277.40(16) Å3, Z = 2, R gt (F) = 0.0444, wR ref (F2) = 0.1048, T = 170.00 K.

CCDC no.: 2143608

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colorless needle
Size: 0.12 × 0.07 × 0.03 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.13 mm−1
Diffractometer, scan mode: Bruker D8 VENTURE, φ and ω
θmax, completeness: 26.4°, >99%
N(hkl)measured, N(hkl)unique, Rint: 2434, 1039, 0.041
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 816
N(param)refined: 83
Programs: Bruker [1], Olex2 [2], SHELX [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
C1 0.9514 (9) 0.3780 (4) 0.4619 (7) 0.0364 (10)
H1 1.013437 0.302034 0.411596 0.044*
C2 1.0068 (11) 0.4861 (4) 0.3712 (7) 0.0394 (10)
H2 1.116484 0.496740 0.244566 0.047*
C3 0.7553 (10) 0.5215 (4) 0.6425 (7) 0.0308 (10)
C4 0.7016 (12) 0.3078 (4) 0.7916 (9) 0.0446 (11)
H4A 0.797145 0.328162 0.941377 0.067*
H4B 0.789234 0.230584 0.750296 0.067*
H4C 0.460015 0.302811 0.784807 0.067*
N1 0.7896 (8) 0.4005 (3) 0.6390 (5) 0.0326 (8)
N2 0.8841 (8) 0.5775 (3) 0.4861 (5) 0.0325 (9)
N3 0.5935 (9) 0.5835 (3) 0.8032 (6) 0.0381 (10)
O1 0.4374 (9) 0.5250 (3) 0.9258 (5) 0.0500 (9)
O2 0.6122 (9) 0.6930 (3) 0.8070 (6) 0.0574 (11)

Source of material

All of reagents were purchased with analysis grade. In representative experiments, 3.39 g (30 mmol) 2-nitroimidazole were dissolved in 15 mL N,N-dimethylformamide (DMF), then 4.26 g (30 mmol) methyl iodide and 1.68 g (30 mmol) potassium hydroxide (KOH) were added the target compound were obtained by reaction at 353 K for 3 h. Then cooled to room temperature and the crystals of the title compound were obtained by slow evaporation at 293 K.

Experimental details

Using Olex2 [2], the structure was solved with the XT [3] structure solution program using Intrinsic Phasing and refined with the ShelXL [4] refinement package . All H atoms were positioned geometrically and treated as riding, Uiso(H) = 1.2Ueq(C).

Comment

Many imidazoles have been studied in recent years [5, 6], even as anticancer agents and inhibitors [7], [8], [9]. The title compound 1-methyl-2-nitroimidazol is expected to have high research value. Here we report the crystal structure of the title compound (cf. the figure).

The asymmetric unit of the title structure contains one target molecule (see the figure). All geometric parameters in the title molecule are in the expected ranges [10].


Corresponding author: Jun Yuan, Shanxi College of Technology, Shuozhou 036000, Shanxi Province, P. R. China, E-mail:

Acknowledgments

We thank the Center of Testing and Analysis, Shanghai Institute, for support.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SAINT, APEX2 and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2009.Search in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar

5. Ziemer, L., Evans, S., Kachur, A., Shuman, A., Cardi, C., Jenkins, W., Karp, J., Alavi, A., Dolbier, W., Koch, C. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur. J. Nucl. Med. Mol. Imag. 2003, 30, 259–266; https://doi.org/10.1007/s00259-002-1037-5.Search in Google Scholar

6. Martin, S. J., O’Brien, J. E., Dowling, J., Mcbriety, V. J., Krezel, I . New derivatives of imidazole as potential anticancer agents. Farmaco 1998, 53, 342–345 https://doi.org/10.1016/s0014-827x(98)00031-7.Search in Google Scholar

7. Makawana, J. A., Sangani, C. B., Lin, L., Zhu, H. L. Schiff’s base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett 2014, 24, 1734–1736; https://doi.org/10.1016/j.bmcl.2014.02.041.Search in Google Scholar PubMed

8. Ali, E. M. H., Abdel-Maksoud, M. S., Ammar, U. M., Mersal, K. I., Yoo, K. H., Jooryeong, P., Oh, C.-H. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF V600E inhibitors. Bioorg. Chem. 2020, 106, 104508; https://doi.org/10.1016/j.bioorg.2020.104508.Search in Google Scholar PubMed

9. Narasimhan, B., Sharma, D., Kumar, P. Biological importance of imidazole nucleus in the new millennium. Med. Chem. Res. 2011, 20, 1119–1140; https://doi.org/10.1007/s00044-010-9472-5.Search in Google Scholar

10. Lizhen, Chen, Pengbao, Lian and Jianlong, Wang. The crystal structure of 1-methyl-2,4-dinitro-5-iodoimidazole, C4H3IN4O4 Z. Kristallogr. N. Cryst. Struct. 2017, 232, 213–214. https://doi.org/10.1515/ncrs-2016-0209.Search in Google Scholar

Received: 2021-12-20
Accepted: 2022-01-21
Published Online: 2022-02-08
Published in Print: 2022-04-26

© 2022 Yanan Qiao et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of {2,2′-{cyclohexane-1,2-diylbis[(azanylylidene)methylylidene]}bis(2,4-dibromophenolato)-κ4 N,N′,O,O′}copper(II) ─ diethylformamide (1/1), C23H23Br4CuN3O3
  4. The crystal structure of 2-(2-methyl-6-phenyl-4H-pyran-4-ylidene)-1H-indene-1,3(2H)-dione, C21H14O3
  5. Crystal structure of bis((1-methylbenzimidazol-2-yl)methyl)amine, C18H19N5
  6. Crystal structure of (E)-N′-(1-(2-hydroxy-4-methoxyphenyl)ethylidene) isonicotinohydrazide, C15H15N3O3
  7. Crystal structure of 2-((4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetonitrile, C15H11N5S
  8. The crystal structure of 2,2′-((1E,1′E)-hydrazine-1,2-diylidenebis(methaneylylidene))bis(4-chlorophenol), C14H10Cl2N2O2
  9. Dichlorido-{2,6-bis(4,5-dihydro-1H-pyrazol-3-yl)pyridine-κ3 N,N′,N″}zinc(II), C11H9C12N5Zn
  10. The crystal structure of dichlorido-(2-((4-phenyl-2H-1,2,3-triazol-2-yl)methyl)pyridine-κ2N,N′)palladium(II), C14H12Cl2N4Pd
  11. The crystal structure of 1-(N1-benzyl-2-methyl-4-nitro-imidazol-5-yl)-4-(prop-2-yn-1-yl) piperazine, C18H21N5O2
  12. Crystal structure of (μ4-(1,2,4,5-tetra(1,2,4-triazol-1-ylmethyl)-benzene-κ4N:N1:N2:N3)disilver(I) diperchlorate
  13. The crystal structure of 1-(2-bromoethane)-4-amine-3,5-dinitropyrazole, C5H6Br1N5O4
  14. Crystal structure of (E)-1-(4-benzyl-3,5-dioxomorpholin-2-ylidene)ethyl acetate, C15H15N1O5
  15. The crystal structure of poly[diaqua-(μ2-1,2,4,5-tetrakis(1,2,4-triazol-1-ylmethyl)-benzene-κ2N:N′)-bis(μ3-terephthalato-κ3O:O′:O′′)dicadmium(II)], C17H15N6O5Cd
  16. Crystal structure of (E)-N′-(1-(5-chloro-2-hydroxyphenyl) ethylidene)thiophene-2-carbohydrazide, C13H11ClN2O2S
  17. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylato-k2 N,O)cobalt(II)]-monohydrate, C36H26N4O5Co
  18. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-3-hydroxybenzo-hydrazide monohydrate, C14H13ClN2O4
  19. Crystal structure of 1,1′-(methylene)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C42H30N14Ni2S8
  20. Crystal structure of 1,1′-(1,2-ethanediyl)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2 S:S)nickel(II), C20H14N6NiS4
  21. The crystal structure of 1-methyl-1H-pyrazol-2-ium nitrate, C4H7O3N3
  22. The crystal structure of 4,4′-diselanediylbis(8-(hexyloxy)-3,6-dimethyl-1-(piperidin-1-yl)isoquinoline-7-carbonitrile), C46H60N6O2Se2
  23. The crystal structure of tris(6-methylpyridin-2-yl)phosphine selenide, C18H18N3PSe
  24. The crystal structure of 1,2-bis(2,4-dinitro-1H-imidazol-1-yl)ethane ─ acetone (1/1), C11H12N8O9
  25. Crystal structure of [diaqua[2,2′-(1,2-phenylene)bis(1H-imidazole-4-carboxylato-5-carboxy)-κ4N,N′,O,O′]nickel(II)] tetrahydrate, C16H12N4NiO10·4H2O
  26. The crystal structure of tris(4-methyl-1H-pyrazol-1-yl)methane, C13H16N6
  27. The crystal structure of 5,6-dichloro-2-(quinolin-8-yl)isoindoline-1,3-dione, C17H8Cl2N2O2
  28. Crystal structure of (E)-(2-methoxy-benzylidene)-(4-[1,2,4]triazol-1-yl-phenyl)-amine, C16H14N4O
  29. The crystal structure of (Z)-2-(4-(4-bromophenyl)thiazol-2-yl)-4-(3-hydroxybut-2-enoyl)-5-methyl -1,2-dihydro-3H-pyrazol-3-one – methanol (1/1), C18H18N3O4S
  30. Crystal structure of tetraaqua-tris(nitrato-κ2 O,O′) erbium(III) monohydrate, Er(NO3)3·5H2O, H10ErN3O14
  31. The crystal structure of 1-methyl-2-nitro-1H-imidazole 3-oxide, C4H5N3O3
  32. The crystal structure of 1-methyl-2-nitroimidazole, C4H5N3O2
  33. The crystal structure of 2-carboxyl-4-nitroimidazole monohydrate, C4H5N3O5
  34. Crystal structure of bis[hydrido-hexaphenylcarbodiphosphoran][tetra-trifluoromethyl-(μ-diiodo)-diplatinat]
  35. The crystal structure of poly[μ2-aqua- aqua-(μ3-(E)-2-(4-((2-carbamothioylhydrazineylidene)methyl)phenoxy)acetato-κ3 O:S:S)sodium(I)], C10H14N3O5SNa
  36. The twinned crystal structure of [4,4′-bipyridine]-1,1′-diium hexachloridostannate(IV), C10H10N2SnCl6
  37. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylate-k2 N,O)copper(II)], C34H24N4O4Cu
  38. Crystal structure of trans-1,2-bis(pyridinium-4-yl) ethylene bis(2-carboxy-4-bromobenzoate) – water (1/4), C14H14BrNO6
  39. Crystal structure of poly[diaqua-(μ3-fumarato)-(μ3-maleato)-(μ4-1,2,4,5-tetrakis((1H-1,2,4-triazol-1-yl)methyl)benzene)tetracadmium(II)] dihydrate, C34H32N12O9Cd4
  40. Crystal structure of a second modification of Pachypodol, C18H16O7
  41. Crystal structure of methyl 2-(4-(2-(cyclopentyl-amino)-1-(N-(4-methoxyphenyl)-1-methyl-5-phenyl-1-H-pyrazole-3-carboxamido)-2-oxoethyl)phenyl)acetate, C34H36N4O5
  42. The crystal structure of catena-poly[(m2-4,4′-bipyridine-κ2 N:N)-bis(6-phenylpyridine-2-carboxylato-κ2 N,O) zinc(II)], C34H24N4O4Zn
  43. The crystal structure of hexaquamagnesium(II) (2,4-bis(nitroimino)-6-oxo-1,3,5-triazinane-1,3-diide), C3H15MgN7O12
  44. The crystal structure of 7-Bromo-2-(4-chloro-phenyl)-quinoxaline, C14H9BrClN2
  45. Crystal structure of methyl 4-{[4-(4-cyanobenzamido)phenyl]amino}benzofuro[2,3-d]pyrimidine-6-carboxylate, C26H17N5O4
  46. The crystal structure of (4SR)-7-(3,4-dichlorobenzyl)-4,8,8-trimethyl-7,8-dihydroimidazo[5,1c][1,2,4]triazine-3,6(2H,4H)-dione, C15H16Cl2N4O2
  47. Crystal structure of catena-poly[{μ2-3-carboxy-2,3-bis((4-methylbenzoyl)oxy)propanoato-κ2 O:O′}tris(methanol-κ1 O)lanthanum(III)], C63H63LaO27
Downloaded on 21.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2021-0482/html
Scroll to top button